Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. | Mol Cancer | 2023 | 36617554 | PubTator, text mining | PubMed |
| Neoantigens: promising targets for cancer therapy. | Signal Transduct Target Ther | 2023 | 36604431 | PubTator, text mining | PubMed |
| Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective. | Cells Tissues Organs | 2023 | 36599319 | PubTator, text mining | PubMed |
| Exploration of aminoacyl-tRNA synthetases from eukaryotic parasites for drug development. | J Biol Chem | 2023 | 36596362 | PubTator, text mining | PubMed |
| CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. | J Immunother Cancer | 2023 | 36593069 | PubTator, text mining | PubMed |
| Advanced T and Natural Killer Cell Therapy for Glioblastoma. | J Korean Neurosurg Soc | 2023 | 36588388 | PubTator, text mining | PubMed |
| Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. | Ann Rheum Dis | 2023 | 36572507 | PubTator, text mining | PubMed |
| T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy. | Biomaterials | 2023 | 36566554 | PubTator, text mining | PubMed |
| Modifying enzyme replacement therapy - A perspective. | J Cell Mol Med | 2023 | 36566487 | PubTator, text mining | PubMed |
| Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? | J Cancer Res Clin Oncol | 2023 | 36564524 | PubTator, text mining | PubMed |
| The potential for Treg-enhancing therapies in transplantation. | Clin Exp Immunol | 2023 | 36562079 | PubTator, text mining | PubMed |
| Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy. | Gene Ther | 2023 | 36529796 | PubTator, text mining | PubMed |
| Empowering gene delivery with protein engineering platforms. | Gene Ther | 2023 | 36529795 | PubTator, text mining | PubMed |
| IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. | Blood Adv | 2023 | 36521101 | PubTator, text mining | PubMed |
| Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+ T cells. | Mol Ther Methods Clin Dev | 2023 | 36514789 | PubTator, text mining | PubMed |
| CAF-immune cell crosstalk and its impact in immunotherapy. | Semin Immunopathol | 2023 | 36480035 | PubTator, text mining | PubMed |
| Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics. | Bioact Mater | 2023 | 36471724 | PubTator, text mining | PubMed |
| Flagellin-specific human CAR Tregs for immune regulation in IBD. | J Autoimmun | 2023 | 36470208 | PubTator, text mining | PubMed |
| Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. | Blood Adv | 2023 | 36469024 | PubTator, text mining | PubMed |
| Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes. | Clin Cancer Res | 2023 | 36454122 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=43